Related Experiment Video
Updated: Apr 14, 2026
Inspiratory Muscle Training as an Adjunct to the Treatment of Weaning Failure in Critically Ill Patients: A Practical Guide
Published on: January 30, 2026
Inhaled β2-Agonist Therapy Increases Functional Residual Capacity in Mechanically Ventilated Children With
Musaab A Ramsi1, Michael Henry, Carlos E Milla
11Division of Pediatric Critical Care Medicine, Sheikh Khalifa Medical City (SKMC) in affiliation with Cleveland Clinic, Abu Dhabi, United Arab Emirates. 2Respiratory Therapy Department, Lucile Packard Children's Hospital at Stanford University, Palo Alto, CA. 3Division of Pulmonary Medicine, Center for Excellence in Pulmonary Biology, Stanford University School of Medicine, Stanford, CA. 4Department of Pediatrics, Center for Excellence in Pulmonary Biology, Stanford University School of Medicine, Stanford, CA.
Insights
Aerosolized albuterol increased functional residual capacity in mechanically ventilated children with respiratory failure. This study suggests a potential new lung recruitment strategy for pediatric patients.
Area of Science:
- Pediatric Critical Care Medicine
- Respiratory Physiology
- Pharmacology
Background:
- Mechanical ventilation is crucial for managing pediatric respiratory failure.
- Understanding interventions that optimize lung function in these patients is essential.
- Aerosolized medications are commonly used, but their specific effects on lung mechanics require further investigation.
Purpose of the Study:
- To evaluate the impact of aerosolized albuterol on functional residual capacity (FRC) in mechanically ventilated children.
- To assess changes in lung mechanics, oxygen consumption, and hemodynamics following albuterol administration.
- To test the hypothesis that albuterol modifies key respiratory parameters in pediatric respiratory failure.
Main Methods:
- A prospective, self-controlled clinical trial was conducted in a 24-bed pediatric intensive care unit (PICU).
- Twenty-five children (aged 1-18 years) receiving mechanical ventilation for respiratory failure were enrolled.
- Functional residual capacity (FRC) was measured using nitrogen washout, alongside respiratory mechanics, oxygen consumption, and vital signs before and after albuterol administration.
Main Results:
- Baseline FRC was significantly lower than predicted (53%).
- Aerosolized albuterol increased FRC by 18.3% (p=0.008).
- No overall change in airway resistance was observed, but a decrease was noted in patients with endotracheal tube size ≥ 4.0 mm (p<0.02). Heart rate increased (p<0.0001), but oxygen consumption remained unchanged.
Conclusions:
- Aerosolized albuterol effectively increases FRC in pediatric patients with respiratory failure.
- It may favorably enhance pulmonary mechanics, presenting a potential novel lung recruitment strategy.
- Further research is warranted to explore its role in optimizing respiratory support for children.
Objectives:
To test the hypothesis that in mechanically ventilated children with respiratory failure, aerosolized albuterol modifies functional residual capacity, lung mechanics, oxygen consumption, and hemodynamics.
Design:
Prospective, self-control clinical trial.
Setting:
A 24-bed PICU in a quaternary care, academic children's hospital.
Patients:
25 children (age range, 1-18 yr) undergoing mechanical ventilation to treat respiratory failure. Entry criteria included previously prescribed inhaled β2 agonists. Physiologic measurements were performed prior to and 20 minutes after administration of aerosolized albuterol solution. Functional residual capacity was determined via nitrogen washout.
Interventions:
Functional residual capacity, oxygen consumption, respiratory mechanics, and vital signs were measured were measured prior to and 20 minutes after administration of aerosolized albuterol solution. Functional residual capacity was determined via nitrogen washout.
Measurement And Main Results:
At baseline, functional residual capacity is only 53% of predicted. After aerosolized albuterol, functional residual capacity increased by 18.3% (p = 0.008). Overall, aerosolized albuterol had no effect on airway resistance. However, in patients with an endotracheal tube size of more than or equal to 4.0 mm, resistance decreased from 33 ± 3 to 25 ± 3 (p < 0.02). Inhaled albuterol administration had no effect on oxygen consumption despite an increase in heart rate from 116 ± 2 to 128 ± 2 beats/min (p < 0.0001).
Conclusions:
In pediatric patients with respiratory failure, aerosolized albuterol increases functional residual capacity without a decrease in resistance. In infants and children, aerosolized albuterol might favorably enhance pulmonary mechanics and thereby represent a novel strategy for lung recruitment in children with respiratory failure.
Related Concept Videos
01:29Acute Respiratory Failure-V
Ensure that patients are monitored continuously for their response to therapy, including changes in...
01:23Mechanical Ventilation III: Noninvasive Ventilation
Noninvasive Positive-Pressure Ventilation...
01:23Mechanical Ventilation II: Invasive Ventilation
Negative-Pressure Ventilators
Negative-pressure ventilators create a vacuum around the chest or body to draw air into the lungs, simulating breathing. This method does not require an...
01:30Acute Respiratory Failure-III
01:26COPD: Management Using Bronchodilators and Corticosteroids
01:17Drugs Used in Lower Respiratory Disorders: Overview
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...